The past three decades have witnessed an explosion in information regarding the genetic mutations underlying predisposition to common malignancies. Discoveries are now being made regarding genomic variants associated with disease risk for, and outcome following, treatment for cancer. Responsible translation of these discoveries to medical practice requires attention to principles of clinical utility as well as social and ethical aspects.
Copyright 2010 Elsevier Inc. All rights reserved.